| Biomarker ID | 872 |
| PMID | 22355332 |
| Year | 2012 |
| Biomarker | cDNA FLJ55673 + cDNA FLJ58564 + Ceruplasmin + Complement C5 + Alpha-1-antichymotrypsin + Complement component C9b + cDNA FLJ54228 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated : [cDNA FLJ55673 (1.1 fold)+ cDNA FLJ58564 (1.1 fold)+ Ceruplasmin (1.1 fold) + Complement C5 (1.1 fold) + Alpha-1-antichymotrypsin (1.2 fold) + Complement component C9b (1.2 fold) + cDNA FLJ54228 (1.5 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | BPH Vs Non Progressing Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Samples were collected from 4 groups with 5 samples each:benign prostatic hyperplasia (BPH); ii) localised cancer with no evidence of progression, (non-progressing) (iii) localised cancer with evidence of biochemical progression, (progressin), and (iv) bone metastasis at presentation (metastatic). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p ≤0.01 |
| Method Used | 4-plex iTRAQ |
| Clinical | No |
| Remarks | represents biomarkers assessed individualy, + represents biomarkers assessed as a pair or panel |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CP, C5, SERPINA3, C9 |